RU2006144397A - ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ - Google Patents

ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ Download PDF

Info

Publication number
RU2006144397A
RU2006144397A RU2006144397/14A RU2006144397A RU2006144397A RU 2006144397 A RU2006144397 A RU 2006144397A RU 2006144397/14 A RU2006144397/14 A RU 2006144397/14A RU 2006144397 A RU2006144397 A RU 2006144397A RU 2006144397 A RU2006144397 A RU 2006144397A
Authority
RU
Russia
Prior art keywords
factor viia
factor
intracerebral hemorrhage
equivalent
coagulation
Prior art date
Application number
RU2006144397/14A
Other languages
English (en)
Russian (ru)
Inventor
Элизабет ЭРХАРДСЕН (DK)
Элизабет ЭРХАРДСЕН
Бретт Э. СКОЛНИК (US)
Бретт Э. СКОЛНИК
Николай Константин БРУН (DK)
Николай Константин БРУН
Original Assignee
Ново Нордиск Хелс Кеа Аг (Ch)
Ново Нордиск Хелс Кеа Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск Хелс Кеа Аг (Ch), Ново Нордиск Хелс Кеа Аг filed Critical Ново Нордиск Хелс Кеа Аг (Ch)
Publication of RU2006144397A publication Critical patent/RU2006144397A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
RU2006144397/14A 2004-06-21 2005-06-21 ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ RU2006144397A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200400972 2004-06-21
DKPA200400972 2004-06-21
DKPA200400981 2004-06-23
DKPA200400981 2004-06-23

Publications (1)

Publication Number Publication Date
RU2006144397A true RU2006144397A (ru) 2008-07-27

Family

ID=35058275

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006144397/14A RU2006144397A (ru) 2004-06-21 2005-06-21 ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ

Country Status (13)

Country Link
US (2) US20060019894A1 (ja)
EP (1) EP1761274B1 (ja)
JP (2) JP5523671B2 (ja)
KR (1) KR20070027709A (ja)
AT (1) ATE441430T1 (ja)
AU (1) AU2005253749A1 (ja)
BR (1) BRPI0512316A (ja)
CA (1) CA2570330A1 (ja)
DE (1) DE602005016406D1 (ja)
ES (1) ES2331653T3 (ja)
MX (1) MXPA06015045A (ja)
RU (1) RU2006144397A (ja)
WO (1) WO2005123118A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906993A2 (en) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
SI3096779T1 (sl) * 2014-01-24 2020-03-31 Pfizer Inc. Sestavki in postopki za zdravljenje intracerebralne krvavitve
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1216709A1 (en) * 2000-12-21 2002-06-26 Boehringer Ingelheim Pharma KG Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
CA2436807A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
EP1906993A2 (en) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY

Also Published As

Publication number Publication date
DE602005016406D1 (de) 2009-10-15
US20060019894A1 (en) 2006-01-26
JP5523671B2 (ja) 2014-06-18
US20070243183A1 (en) 2007-10-18
ES2331653T3 (es) 2010-01-12
EP1761274A1 (en) 2007-03-14
BRPI0512316A (pt) 2008-02-26
ATE441430T1 (de) 2009-09-15
EP1761274B1 (en) 2009-09-02
JP2008503543A (ja) 2008-02-07
JP2012197279A (ja) 2012-10-18
WO2005123118A1 (en) 2005-12-29
AU2005253749A1 (en) 2005-12-29
KR20070027709A (ko) 2007-03-09
CA2570330A1 (en) 2005-12-29
MXPA06015045A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
US5942543A (en) Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
Karski et al. Prevention of postbypass bleeding with tranexamic acid and ϵ-aminocaproic acid
RU2006144397A (ru) ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ
SE443510B (sv) Sett att framstella medel for forbettring av genomblodning och sarlekning, innehallande extrakt fran blod som befriats fran eggvita
Flordal et al. Use of desmopressin to prevent bleeding complications in patients treated with aspirin
Smith Daflon 500 mg and venous leg ulcer: new results from a meta-analysis
Pollack Wound healing: a review. IV. Systemic medications affecting wound healing
US3224942A (en) Anti-inflammatory, anti-edema and anti-thrombi drug
Amer et al. Correlation between international normalized ratio values and sufficiency of two different local hemostatic measures in anticoagulated patients
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
Jabalameli et al. Evaluation of topical tranexamic acid on intraoperative bleeding in endoscopic sinus surgery
EP1086099A4 (en) COMPOUNDS BASED ON SULFONIC ACID OR SULFONYLAMINO N- (HETEROARALKYL) -AZAHETEROCYCLYLAMIDE
Lawrence Drug management in skin surgery
WO2001082919A3 (en) Methods of and compounds for inhibiting calpains
Cacciola et al. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study
US7198786B2 (en) Method for the reduction or prevention of post-surgical adhesion formation
CN110721334A (zh) 一种止血创伤敷料及其制备方法
Gangarosa et al. A clinical evaluation of local anaesthetic solutions containing graded epinephrine concentrations
US5314881A (en) Use of phosphomycin and the pharmaceutically acceptable salts thereof as a topical cicatrizer
WO2003013548A1 (fr) Composition medicale a usage externe destinee au traitement des dermatoses
EP1068868A2 (en) Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
Bump et al. Fibrinolysis: a possible factor in the control of postoperative hemorrhage in the patient with hemophilia
EP1240900A4 (en) MEDICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THROMBOPATHY ASSOCIATED HEMORRHAGIC DISEASES
Jash Epistaxis—topical use of epsilon-aminocaproic acid in its management
Conrad et al. The Australian polidocanol (aethoxysklerol) study: results at 1 year

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090824